Sangamo Therapeutics (NASDAQ:SGMO) Given “Buy” Rating at HC Wainwright

Sangamo Therapeutics (NASDAQ:SGMO)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They presently have a $10.00 price objective on the biopharmaceutical company’s stock.

Other equities research analysts have also recently issued research reports about the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sangamo Therapeutics in a research report on Thursday, January 22nd. Wall Street Zen cut Sangamo Therapeutics to a “strong sell” rating in a research report on Saturday, January 31st. Finally, Barclays reissued an “equal weight” rating and issued a $1.00 price target (down from $5.00) on shares of Sangamo Therapeutics in a research report on Friday, November 7th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $4.33.

Sangamo Therapeutics Price Performance

Shares of NASDAQ SGMO opened at $0.40 on Tuesday. Sangamo Therapeutics has a twelve month low of $0.35 and a twelve month high of $1.24. The firm has a market cap of $134.60 million, a PE ratio of -0.91 and a beta of 1.28. The business has a fifty day simple moving average of $0.44 and a two-hundred day simple moving average of $0.51.

Hedge Funds Weigh In On Sangamo Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of SGMO. World Investment Advisors grew its position in Sangamo Therapeutics by 88.5% during the 3rd quarter. World Investment Advisors now owns 42,611 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 20,000 shares during the last quarter. R Squared Ltd purchased a new position in Sangamo Therapeutics in the 2nd quarter worth $28,000. XTX Topco Ltd acquired a new stake in Sangamo Therapeutics during the 2nd quarter worth about $41,000. Engineers Gate Manager LP grew its stake in Sangamo Therapeutics by 101.7% during the 2nd quarter. Engineers Gate Manager LP now owns 87,425 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 44,078 shares during the last quarter. Finally, Prelude Capital Management LLC acquired a new position in shares of Sangamo Therapeutics in the third quarter valued at about $67,000. 56.92% of the stock is owned by hedge funds and other institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.